12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ProstVac: Phase III started

Bavarian's BN ImmunoTherapeutics Inc. subsidiary began a double-blind, placebo-controlled, international Phase III trial to evaluate ProstVac with and without granulocyte macrophage colony-stimulating factor (GM-CSF) as...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >